<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146260">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860586</url>
  </required_header>
  <id_info>
    <org_study_id>HsuPVR13</org_study_id>
    <secondary_id>MARPVR2013</secondary_id>
    <nct_id>NCT01860586</nct_id>
  </id_info>
  <brief_title>Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.</brief_title>
  <official_title>A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin)
      on the rates of recurrent retinal detachment and scar tissue formation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The effect of intravitreal bevacizumab injections on retinal detachment rate (increase or decrease)</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>This will be assessed by the frequency (occurences) of retinal detachments in patients that have intravitreal bevacizumab injections versus prior patients that did not have intravitreal bevacizumab injections.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effect of intravitreal bevacizumab injections on the development of recurrent Proliferative vitreoretinopathy (PVR).</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if intravitreal bevacizumab injections will increase or decrease the occurences (cases) of recurrent PVR .</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intravitreal bevacizumab injections impact on visual acuity score (change in letters read).</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase or decrease in amount of letters read after intravitreal bevacizumab injections versus control patient that did not receive injections of intravitreal bevacizumab.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinal Detachment</condition>
  <condition>Vitreoretinopathy Proliferative</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>.005 mL of Bevacizumab will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>intravitreal injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD
             due to PVR with planned silicone oil instillation.

        Exclusion Criteria:

          -  Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of
             retinal detachment surgery.

          -  Traction retinal detachment due to proliferative diabetic retinopathy.

          -  Inability to flatten retina completely intraoperatively

          -  Known allergy or contraindication to intravitreal bevacizumab
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WillsEye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Jordan</last_name>
    <phone>215-928-3092</phone>
    <email>research@midatlanticretina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunir Garg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Spirn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Kaiser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omesh Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Maguire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Regillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Ho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Dollin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Brady, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Pitcher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Brian Burke, MPH</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>pvr</keyword>
  <keyword>rd</keyword>
  <keyword>Proliferative Vitreoretinopathy</keyword>
  <keyword>retinal detachment</keyword>
  <keyword>detachment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
